Stock AnalizLemaitre Vascular Inc. LMAT
Medical/Dental Instruments · IPO 2006 · data as of November 13, 2026
Lemaitre Vascular Inc. (LMAT) is a healthcare company listed in the US with a market value of about $1.8B. In the twelve months to September 30, 2026 it had revenue of $269M and net income of $63M, a net margin of 23.5%.
Its overall Stock Analiz score is 3.6 out of 5 (good). The strongest part is future growth (5/5); the weakest is value (1/5).
Key numbers: a P/E of 28.5, a price to free cash flow of 26.7, 5-year revenue growth of 14% a year, a 5-year average ROIC of 9%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 42% below the current price.
Score: 3.6 / 5
Checks passed
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- 5-year average ROIC above 12%
- ROE above 15%
- Share count down over 3 years (buybacks)
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $269M | $250M | $220M | $193M | $162M | $154M | $129M | $117M | $106M | $101M | $89M |
| Net income | $63M | $58M | $44M | $30M | $21M | $27M | $21M | $18M | $23M | $17M | $11M |
| Free cash flow | $67M | $74M | $37M | $29M | $22M | $30M | $32M | $10M | $16M | $16M | $14M |
| EPS (diluted) | $2.75 | $2.52 | $1.93 | $1.34 | $0.93 | $1.25 | $1.04 | $0.88 | $1.13 | $0.86 | $0.55 |
| Net margin | 23.5% | 23.1% | 20.0% | 15.6% | 12.8% | 17.4% | 16.4% | 15.3% | 21.7% | 17.0% | 11.9% |
| ROIC | — | 9.0% | 7.7% | 8.8% | 7.1% | 10.6% | 9.9% | 10.7% | 17.5% | 15.7% | 12.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 7 analysts is $99.29, 27% above the current price; targets range from $81.00 to $132.00; the consensus rating is “Buy”; expected EPS is $2.81 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Lemaitre Vascular’s P/E ratio?
About 28.5, based on the last twelve months of diluted earnings per share (forward P/E about 25.5).
Is Lemaitre Vascular stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 42% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Lemaitre Vascular pay a dividend?
Yes. The dividend yield is about 1.26%, and it has paid dividends for 10 years in our data.
Is Lemaitre Vascular a good stock to buy?
We do not give buy or sell advice. Lemaitre Vascular scores 3.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.